Tertiary Nav - Press Releases Press ReleasesMedia Statements Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None20222021202020192018201720162015201420132012201120102009200820072006 Date Title 1/31/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 1/10/22 Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy 1/6/22 Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference 12/31/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/30/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/17/21 Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development 11/17/21 Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors 11/3/21 Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments 11/2/21 Sarepta Therapeutics to Present at Upcoming Investor Conferences 10/29/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 21 - 30 of 730 Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None20222021202020192018201720162015201420132012201120102009200820072006 Date Title 1/31/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 1/10/22 Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy 1/6/22 Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference 12/31/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/30/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/17/21 Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development 11/17/21 Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors 11/3/21 Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments 11/2/21 Sarepta Therapeutics to Present at Upcoming Investor Conferences 10/29/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 21 - 30 of 730